Assist. Prof. Dr. Changtong YANG | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Assist. Prof. Dr. Changtong YANG | Medicinal Chemistry | Best Researcher Award

Assist. Prof. Dr. Changtong YANG , Medicinal Chemistry,  Radiochemist/Chemist at Singapore General Hospital, Singapore

Dr. Chang-Tong Yang is a renowned radiochemist based in Singapore, specializing in radiopharmaceuticals and molecular imaging. He currently serves as an Assistant Professor in the Radiological Science Academic Clinical Programme at Duke-NUS Medical School and as a Radiochemist at Singapore General Hospital. With over two decades of experience, Dr. Yang has made significant contributions to the development of nuclear imaging probes and radiolabeled therapeutics. His research career spans prestigious institutions, including Nanyang Technological University and A*STAR. Dr. Yang is internationally recognized for advancing nanomaterial probes and novel radiolabeling strategies. He has authored impactful publications in top-tier journals, reflecting his innovation in theranostics, radiochemistry, and nanomedicine. With a strong background in academic and clinical research, Dr. Yang continues to shape the future of molecular imaging for personalized medicine. His global education and interdisciplinary expertise make him a leading figure in translational radiochemistry research.

Professional Profile : 

Orcid

Scopus 

Summary of Suitability for Award:

Dr. Chang-Tong Yang exemplifies the qualities of a “Best Researcher Award” recipient. His innovative contributions to radiochemistry and molecular imaging, combined with a strong publication record, interdisciplinary leadership, and global training, establish him as a trailblazer in translational medical research. His work is not only scientifically rigorous but also clinically impactful, directly advancing the field of nuclear medicine. Therefore, he is highly recommended for recognition as a top-tier researcher deserving of this award.

🎓Education:

Dr. Chang-Tong Yang received his Ph.D. in Chemistry from the National University of Singapore (1998–2002), where he laid the foundation for his career in radiochemistry. He further enhanced his expertise with postdoctoral fellowships at three prestigious U.S. institutions: University of Iowa (2003–2005), University of Michigan (2005–2006), and Purdue University (2006–2007), focusing on chemistry and health sciences. These formative years provided Dr. Yang with a multidisciplinary perspective in synthetic chemistry, radiopharmaceutical development, and imaging sciences. His international training exposed him to cutting-edge methodologies and collaborative projects across biomedical research, which he has since translated into innovative imaging solutions. The combination of rigorous education and hands-on research across these top institutions shaped his ability to bridge fundamental science with clinical applications, particularly in nuclear medicine and molecular imaging.

🏢Work Experience:

Dr. Chang-Tong Yang brings extensive professional experience across both academic and clinical research settings. He is currently an Assistant Professor at Duke-NUS Medical School (2020–present) under the Radiological Science ACP, focusing on radiopharmaceutical sciences. Concurrently, he serves as a Radiochemist at Singapore General Hospital (2018–present) in the Department of Nuclear Medicine & Molecular Imaging, where he translates research into clinical practice. Prior to that, he worked as a Senior Scientist at Nanyang Technological University (2014–2018), contributing to molecular imaging initiatives within the Lee Kong Chian School of Medicine. He also held a Senior Scientist role at A*STAR’s Singapore Bio-Imaging Consortium (2007–2014), leading various radiochemistry research programs. Across these roles, Dr. Yang has developed and validated imaging agents, optimized radiolabeling techniques, and led translational studies that impact diagnostic imaging and therapeutic strategies. His multidisciplinary engagements underscore his pivotal role in bridging chemistry and medicine.

🏅Awards: 

While specific awards are not listed in the available data, Dr. Chang-Tong Yang’s extensive contributions to radiopharmaceuticals and molecular imaging reflect a highly respected and impactful career. His appointments at top institutions such as Duke-NUS, A*STAR, and Singapore General Hospital indicate peer recognition and institutional trust. His publications in reputed journals such as Molecules, Nanomaterials, and Drug Discovery Today highlight his standing in the scientific community. His ongoing leadership roles and collaboration with clinicians further underscore professional acknowledgment of his expertise. Dr. Yang’s selection for multiple postdoctoral positions at prestigious U.S. institutions—University of Iowa, University of Michigan, and Purdue University—suggests early recognition of his academic promise. His interdisciplinary contributions to nuclear medicine, nanotechnology, and molecular imaging may have earned him internal institutional awards, research grants, and invitations to present at scientific forums, which commonly accompany such roles.

🔬Research Focus:

Dr. Chang-Tong Yang’s research is centered on radiopharmaceutical science, with a strong emphasis on the development of molecular imaging probes and radiolabeled nanomaterials for diagnostic and therapeutic applications. His expertise lies in designing novel radioisotope-labeled compounds for use in nuclear medicine imaging techniques such as PET and SPECT, targeting cancer and other pathological conditions. He is particularly interested in enhancing the in vivo behavior of nanomaterial-based agents, improving tumor targeting, retention, and safety. Dr. Yang also explores the biocompatibility and stability of these probes, including how formulation and labeling protocols influence their function. His translational work bridges laboratory innovations with clinical imaging requirements, enabling personalized diagnostics and theranostic approaches. Furthermore, he investigates radiochemical compatibility in clinical settings, such as the mixing of imaging agents with contrast media, which supports safe and effective imaging protocols. His work integrates chemistry, imaging, and clinical practice seamlessly.

Publication Top Notes:

1. pH-Induced In Situ Aggregation of Cu₂₋ₓSe-POED with Extended Tumor Retention for Enhanced Chemodynamic/Photothermal Therapy

2. Standard Radio-Iodine Labeling Protocols Impaired the Functional Integrity of Mesenchymal Stem/Stromal Cell Exosomes

3. Radiolabeled Liposomes for Nuclear Imaging Probes

4. Radiochemical Feasibility of Mixing of 99mTc-MAA and 90Y-Microspheres with Omnipaque Contrast

5. Nanomaterial Probes for Nuclear Imaging

6. Positron Emission Tomographic Imaging in Drug Discovery

7. An In Vivo Study of a Rat Fluid-Percussion-Induced Traumatic Brain Injury Model with [11C]PBR28 and [18F]flumazenil PET Imaging

8. Gadolinium-Based Bimodal Probes to Enhance T1-Weighted Magnetic Resonance/Optical Imaging

9. Activatable Cell-Penetrating Peptide Conjugated Polymeric Nanoparticles with Gd-Chelation and Aggregation-Induced Emission for Bimodal MR and Fluorescence Imaging of Tumors

10. Dealing with PET Radiometabolites

11. PET-MR and SPECT-MR Multimodality Probes

 

Dr. Xufen Yu | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Dr. Xufen Yu | Medicinal Chemistry | Best Researcher Award

Dr. Xufen Yu | Medicinal Chemistry | Associate Professor at Fudan University, China

Dr. Xufen Yu is an Associate Professor in the Department of Medicinal Chemistry at Fudan University’s School of Pharmacy. She specializes in drug discovery, chemical biology, and targeted protein degradation, particularly in cancer therapeutics. Before joining Fudan University, she was an Instructor and Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai, where she contributed significantly to pharmacological sciences. Dr. Yu has also held postdoctoral positions at Purdue University and the University of Hawaii at Hilo. She holds a Ph.D. from the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry. Her research has led to numerous high-impact publications in journals such as Journal of Medicinal Chemistry, Oncogene, and Nature Cancer. With extensive expertise in PROTAC-based therapeutics and epigenetic regulation, Dr. Yu continues to make significant contributions to the field of medicinal chemistry and targeted cancer therapy.

Professional Profile : 

Google Scholar

Orcid

Scopus  

Summary of Suitability for Award:

Dr. Xufen Yu is an exceptionally accomplished researcher in medicinal chemistry, with significant contributions to drug discovery, targeted protein degradation, and epigenetics. Her extensive academic background, including a Ph.D. from the Chinese Academy of Sciences and postdoctoral research at prestigious institutions such as Purdue University and the Icahn School of Medicine at Mount Sinai, demonstrates her expertise in chemical biology and small-molecule therapeutics. She has consistently advanced the field through high-impact publications, innovative research, and groundbreaking discoveries in PROTACs and DUBTACs, which have transformed targeted cancer therapy.  Given her outstanding achievements, innovative research, and contributions to medicinal chemistry, Dr. Xufen Yu is highly suitable for the “Best Researcher Award”. Her pioneering work in targeted protein degradation, combined with her international recognition and research excellence, makes her a strong candidate. Her research has not only advanced scientific knowledge but also holds significant promise for therapeutic applications, reinforcing her eligibility for this distinguished honor.

🎓Education:

Dr. Xufen Yu earned her Ph.D. in Organic Chemistry from the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry, in 2011. Her doctoral research focused on synthetic organic chemistry and drug discovery. Prior to that, she completed her undergraduate studies at Anhui University, Hefei, China, earning a Bachelor’s degree in Chemistry in 2006. With a strong academic foundation, Dr. Yu developed expertise in medicinal chemistry, chemical biology, and targeted protein degradation. Her educational journey equipped her with extensive knowledge of molecular design, synthetic methodologies, and structure-activity relationship studies, laying the groundwork for her future contributions to pharmacological sciences. Her rigorous training in organic synthesis and chemical biology has driven her impactful research in developing novel therapeutics, particularly in targeted protein degradation and epigenetic regulation.

🏢Work Experience:

Dr. Xufen Yu has had a distinguished career in academia and research, with extensive postdoctoral and faculty experience. She is currently an Associate Professor in the Department of Medicinal Chemistry at Fudan University, Shanghai, China. Before joining Fudan, she was an Instructor in the Department of Pharmacological Science at the Icahn School of Medicine at Mount Sinai, New York (2021–2022), following a postdoctoral fellowship at the same institution from 2017 to 2020. She also worked as a postdoctoral fellow in Chemistry at Purdue University (2013–2014) and in Pharmaceutical Science at the University of Hawaii at Hilo (2011–2013). Through these roles, she has contributed significantly to medicinal chemistry, focusing on drug discovery, targeted protein degradation, and cancer therapeutics. Her work across multiple prestigious institutions reflects her expertise in interdisciplinary research, integrating chemistry and pharmacology to develop novel small-molecule therapeutics.

🏅Awards: 

Dr. Xufen Yu has been recognized for her outstanding contributions to medicinal chemistry and drug discovery. She has received multiple awards and research grants for her pioneering work in targeted protein degradation and epigenetics. Her innovative research has been acknowledged with prestigious fellowships and funding from institutions such as the National Institutes of Health (NIH) and the Chinese Academy of Sciences. Additionally, she has been honored for her significant publications in high-impact journals, receiving accolades for breakthrough studies on PROTACs and epigenetic regulators in cancer therapy. Her commitment to scientific excellence has led to invitations as a speaker at international conferences, where she has shared her expertise in medicinal chemistry. Dr. Yu’s contributions have been instrumental in advancing chemical biology and therapeutic discovery, making her a well-respected figure in her field.

🔬Research Focus:

Dr. Xufen Yu’s research focuses on the development of novel therapeutic strategies targeting disease-related proteins, particularly in cancer and metabolic disorders. Her expertise lies in targeted protein degradation, including the design and synthesis of PROTACs (Proteolysis Targeting Chimeras) and DUBTACs (Deubiquitinase Targeting Chimeras). She has explored epigenetic regulation in cancer therapy, investigating how small molecules can modulate oncogenic transcription factors and chromatin regulators. Her work also includes studying the role of ubiquitin-proteasome and autophagy systems in disease mechanisms, aiming to develop highly selective small-molecule therapeutics. Through interdisciplinary approaches combining medicinal chemistry, chemical biology, and pharmacology, she has contributed to advancing targeted cancer treatments. Dr. Yu’s research has led to the discovery of several potent and selective degraders for oncogenic proteins such as EZH2, WDR5, and USP7, paving the way for new treatment modalities in oncology.

Publication Top Notes:

Macrocyclic drugs and synthetic methodologies toward macrocycles
Authors: X Yu, D Sun
Citations: 276
Year: 2013

Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism
Authors: AJ Bott, J Shen, C Tonelli, L Zhan, N Sivaram, YP Jiang, X Yu, V Bhatt, …
Citations: 155
Year: 2019

Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders
Authors: M Cheng, X Yu, K Lu, L Xie, L Wang, F Meng, X Han, X Chen, J Liu, …
Citations: 151
Year: 2020

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Authors: J Wang, X Yu, W Gong, X Liu, KS Park, A Ma, YH Tsai, Y Shen, T Onikubo, …
Citations: 134
Year: 2022

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Authors: X Yu, D Li, J Kottur, Y Shen, HS Kim, KS Park, YH Tsai, W Gong, J Wang, …
Citations: 103
Year: 2021

Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders
Authors: Y Shen, G Gao, X Yu, H Kim, L Wang, L Xie, M Schwarz, X Chen, …
Citations: 84
Year: 2020

Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery
Authors: AM Chiarella, KV Butler, BE Gryder, D Lu, TA Wang, X Yu, S Pomella, …
Citations: 77
Year: 2020

Cationic Palladium Complex Catalyzed Diastereo-and Enantioselective Tandem Annulation of 2-Formylarylboronic Acids with Allenoates
Authors: X Yu, X Lu
Citations: 57
Year: 2009

AKT degradation selectively inhibits the growth of PI3K/PTEN pathway–mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B
Authors: J Xu, X Yu, TC Martin, A Bansal, K Cheung, A Lubin, E Stratikopoulos, …
Citations: 51
Year: 2021

Design, synthesis, and evaluation of potent, selective, and bioavailable AKT kinase degraders
Authors: X Yu, J Xu, L Xie, L Wang, Y Shen, KM Cahuzac, X Chen, J Liu …
Citations: 42
Year: 2021

Assoc. Prof. Dr. Ranjan Khunt | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Assoc. Prof. Dr. Ranjan Khunt | Medicinal Chemistry | Best Researcher Award

Assoc. Prof. Dr. Ranjan Khunt , Saurashtra University , India

Dr. Ranjan C. Khunt is an accomplished Associate Professor in the Department of Chemistry at Saurashtra University, Rajkot, with over 25 years of teaching and 20 years of research experience. He holds an M.Sc. and Ph.D. from Saurashtra University, specializing in Heterocyclic Medicinal Chemistry, Nano-Science, and Spectroscopy. Dr. Khunt has significantly contributed to nano-science and method development, focusing on advancing spectroscopy and medicinal chemistry. He has published 105 research papers and holds 7 patents. With a track record of guiding 14 research students and mentoring 3 current students, Dr. Khunt is committed to fostering the next generation of chemists. His leadership is further demonstrated by his academic service, including serving as a member of the National Magnetic Resonance Society and receiving recognition for his teaching excellence and research achievements.

Professional Profile

Google Scholar

Orcid

Scopus

Summary of Suitability for Award:

Dr. Ranjan C. Khunt is highly suitable for the Best Researcher Award due to his remarkable contributions in Medicinal Chemistry, Nano-Science, and Spectroscopy. With over 20 years of research experience, Dr. Khunt has authored 105 research papers and holds 7 patents, underscoring his prolific output and innovation in the field. His focus on developing novel heterocyclic compounds with potential medicinal applications, as well as his expertise in nano-materials for environmental and medical purposes, has had a significant impact on both theoretical and applied chemistry. Moreover, his contributions to spectroscopic methods have advanced chemical analysis techniques. Dr. Khunt’s leadership in guiding 14 research students and his mentorship in a wide array of interdisciplinary projects demonstrate his commitment to fostering future researchers. His numerous awards, including the Best Teacher Award and recognition by institutions like the National Magnetic Resonance Society, further solidify his candidacy for this prestigious honor.

🎓Education:

Dr. Ranjan C. Khunt’s educational journey began at Saurashtra University, where he completed both his M.Sc. and Ph.D. in Chemistry. His doctoral research focused on Heterocyclic Medicinal Chemistry, a field that would shape his subsequent career. Throughout his academic journey, he gained extensive knowledge in Nano-Science and Spectroscopy, which became key areas of his research expertise. Dr. Khunt’s research interests in these fields reflect a strong foundation in both theoretical and practical aspects of chemistry. His academic qualifications provided him with a robust understanding of the intersection between chemistry, medicinal applications, and cutting-edge technological developments. Dr. Khunt’s commitment to his education extended beyond the classroom as he engaged in continuous learning and contributed to the field’s advancement through teaching and research at Saurashtra University, where he remains an influential figure in the academic community.

🏢Work Experience:

Dr. Ranjan C. Khunt has a distinguished teaching and research career spanning over 25 years. He has been an Associate Professor at the Department of Chemistry, Saurashtra University, Rajkot, for more than two decades, where he has mentored numerous students and played a pivotal role in the university’s academic development. His expertise spans Heterocyclic Medicinal Chemistry, Nano-Science, Spectroscopy, and Method Development and Validation. With 20 years of research experience, Dr. Khunt has led groundbreaking work in these fields, contributing to the development of new methods and technologies. In addition to his teaching responsibilities, he has guided 14 research students, fostering a research-driven environment at the university. Dr. Khunt’s academic career is also marked by 17 invitations from other institutions, reflecting his reputation as a leader in his field. His research projects have resulted in valuable advancements, and his work continues to influence the future of chemistry education and research.

🏅Awards: 

Dr. Ranjan C. Khunt’s academic and professional excellence has been recognized through various prestigious awards and honors. He was awarded the Best Teacher Award by the Institute of Scholars, which acknowledged his exceptional teaching abilities and commitment to student development. In addition, he received the Nation Builder’s Award from the Rotary Club of Rajkot Prime, a testament to his contributions to education and society. Dr. Khunt was honored with the Fast Track Young Scientist Fellowship, which highlighted his emerging role in advancing scientific research. He also serves as an Executive Committee Member of the National Magnetic Resonance Society, Bangalore, an esteemed position that reflects his influence in the field of spectroscopy. These recognitions, along with 6 research projects and his impressive publication record, underscore Dr. Khunt’s dedication to the scientific community, educational excellence, and innovation.

🔬Research Focus:

Dr. Ranjan C. Khunt’s research focuses on the intersection of Medicinal Chemistry, Nano-Science, and Spectroscopy, areas in which he has made significant advancements. His expertise in Heterocyclic Chemistry has led to the development of novel compounds with medicinal applications, especially those aimed at improving health outcomes. Dr. Khunt’s work in Nano-Science is driven by the exploration of nanomaterials for use in various chemical processes and their applications in drug delivery systems, diagnostics, and therapeutic interventions. Additionally, his contributions to Spectroscopy and Method Development have been fundamental in advancing analytical techniques, aiding in precise measurement and characterization of chemical compounds. His research aims to bridge the gap between fundamental chemical knowledge and practical applications in medicine, pharmaceuticals, and environmental chemistry. Dr. Khunt’s work is critical for advancing both the theoretical and practical aspects of modern chemistry, especially in sustainable and health-related areas.

Publication Top Notes:

Synthesis, antitubercular evaluation and 3D-QSAR study of N-phenyl-3-(4-fluorophenyl)-4-substituted pyrazole derivatives
Authors: RC Khunt, VM Khedkar, RS Chawda, NA Chauhan, AR Parikh, …
Journal: Bioorganic & Medicinal Chemistry Letters
Citations: 109
Year: 2012

Synthesis of some new heterocyclic compounds with potential biological activity
Authors: DP Bhoot, RC Khunt, VK Shankhavara, HH Parekh
Journal: Journal of Sciences, Islamic Republic of Iran
Citations: 36
Year: 2006

Plant pigments as dietary anticancer agents
Author: RK Upadhyay
Journal: International Journal of Green Pharmacy (IJGP)
Citations: 33
Year: 2018

Synthesis of certain 1, 3, 4-oxadiazoles as potential antitubercular and antimicrobial agents
Authors: SR Dhol, AS Bhimani, RC Khunt, AR Parikh
Journal: Indian Journal of Heterocyclic Chemistry
Citations: 25
Year: 2005

Synthesis and biological evaluation of cyanopyridine and isozazole derivatives
Authors: RC Khunt, NJ Datta, FM Bharmal, GP Mankad, AR Parikh
Journal: Indian Journal of Heterocyclic Chemistry
Citations: 24
Year: 2000

Discovery of hybrid purine-quinoline molecules and their cytotoxic evaluation
Authors: KM Kapadiya, RC Khunt
Journal: Letters in Drug Design & Discovery
Citations: 23
Year: 2019

Synthesis of Purine‐based Triazoles by Copper (I)‐catalyzed Huisgen Azide–Alkyne Cycloaddition Reaction
Authors: K Kapadiya, Y Jadeja, R Khunt
Journal: Journal of Heterocyclic Chemistry
Citations: 23
Year: 2018

Synthesis of some new 4-thiazolidinones as biologically potent agents
Authors: NJ Datta, RC Khunt, AR Parikh
Journal: NISCAIR-CSIR, India
Citations: 23
Year: 2002

Dihedral angle study in Hesperidin using NMR Spectroscopy
Authors: YS Jadeja, KM Kapadiya, HJ Jebaliya, AK Shah, RC Khunt
Journal: Magnetic Resonance in Chemistry
Citations: 21
Year: 2017

UV-Vis spectrophotometric assay determination of oral antiplatelet ticagrelor drug in pharmaceutical formulation: Application to content uniformity
Authors: D Pandya, M Patel, R Ghediya, A Shah, R Khunt
Journal: Journal of Chemical and Pharmaceutical Research
Citations: 20
Year: 2016

 

 

 

 

 

Ola Saleh | Pharmaceutical Analytical Chemistry | Analytical Chemistry Award

Published on by Chemistry Awards

Prof. Ola Saleh| Pharmaceutical Analytical Chemistry | Analytical Chemistry Award

Professor at National Research Centre, Egypt 

Dr. Ola Ahmed Saleh is a distinguished professor at the Medicinal and Pharmaceutical Chemistry Department, National Research Centre, Cairo, Egypt. With extensive experience in pharmaceutical chemistry, she specializes in the synthesis of active pharmaceutical entities and the chiral separation of racemic drugs.

Author Metrics

ORCID Profile

Scopus Profile

Dr. Saleh’s research contributions have garnered significant recognition in the academic community, reflected in numerous citations and the impact of her work on pharmaceutical chemistry. Her publications are frequently referenced, underscoring her influence in the field.

  • Citations: 170 citations from 161 documents
  • Publications: 21 documents
  • h-index: 8

Education

Dr. Saleh holds a Bachelor’s degree in Pharmacy, followed by a Master’s and PhD in Pharmaceutical Chemistry. Her advanced degrees underscore her deep knowledge and expertise in her specialized field of study.

Research Focus

Dr. Saleh’s research focuses on synthesizing biologically active pharmaceutical entities. She has a particular interest in chiral separation and analyzing racemic drugs using high-performance liquid chromatography (HPLC), aiming to improve the efficacy and safety of pharmaceutical compounds.

Professional Journey

Dr. Saleh has a distinguished professional career marked by significant contributions to pharmaceutical chemistry. Her work spans various aspects of drug synthesis and analytical methods, establishing her as a leading figure in her field.

Honors & Awards

Throughout her career, Dr. Saleh has received numerous honors and awards, recognizing her exceptional contributions to pharmaceutical chemistry. These accolades highlight her dedication to research and her impact on the scientific community.

Publications Noted & Contributions

Dr. Saleh has an extensive publication record, with notable works in prestigious journals. Her research includes the synthesis of novel pharmaceutical compounds and the development of validated methods for drug analysis, contributing valuable knowledge to the field of pharmaceutical chemistry.

Title: A validated chromatographic method for simultaneous determination of guaifenesin enantiomers and ambroxol HCl in pharmaceutical formulation

  • Journal: RSC Advances
  • Year: 2015
  • DOI: 10.1039/c5ra19391e
  • EID: 2-s2.0-84946595298
  • Contributors: Saleh, O.A.; Yehia, A.M.; Abd-El Sattar El-Azzouny, A.; Aboul-Enein, H.Y.

Title: Synthesis and Anticonvulsant Activity of Substituted-1,3-diazaspiro[4.5]decan-4-ones

  • Journal: Archiv der Pharmazie
  • Year: 2015
  • DOI: 10.1002/ardp.201500092
  • EID: 2-s2.0-84938418531
  • Contributors: Aboul-Enein, M.N.; El-Azzouny, A.A.S.; Saleh, O.A.; Amin, K.M.; Maklad, Y.A.; Hassan, R.M.

Title: A validated high performance liquid chromatographic (HPLC) assay for nitazoxanide in bulk and in pharmaceutical formulations

  • Journal: Current Pharmaceutical Analysis
  • Year: 2014
  • DOI: 10.2174/1573412910666140506225012
  • EID: 2-s2.0-84904730253
  • Contributors: Saleh, O.A.; El-Azzouny, A.A.; Aboul-Enein, H.Y.; Badawey, A.M.

Title: Analysis of Stiripentol Enantiomers on Several Chiral Stationary Phases: A Comparative Study

  • Journal: Chromatographia
  • Year: 2014
  • DOI: 10.1007/s10337-014-2818-2
  • EID: 2-s2.0-84925489270
  • Contributors: Saleh, O.A.; El-Behairy, M.F.; Badawey, A.M.; El-Azzouny, A.A.; Aboul-Enein, H.Y.

Title: Riluzole: Validation of stability-indicating HPLC, D1 and DD1 spectrophotometric assays

  • Journal: Journal of Chromatographic Science
  • Year: 2014
  • DOI: 10.1093/chromsci/bmt062
  • EID: 2-s2.0-84902196955
  • Contributors: Saleh, O.A.; El-Azzouny, A.A.; Aboul-Enein, H.Y.; Badawey, A.M.

Research Timeline

Dr. Saleh’s research timeline spans over two decades, beginning in the late 1990s. Her sustained research efforts have continuously advanced the understanding of drug synthesis and analysis, contributing to the ongoing development of pharmaceutical science.

Collaborations and Projects

Dr. Saleh has collaborated extensively with researchers both locally and internationally. Her projects often involve interdisciplinary approaches, combining synthetic chemistry with advanced analytical techniques to address complex challenges in pharmaceutical research.

Recognition of Expertise in Analytical Chemistry

Dr. Ola Ahmed Saleh has been awarded the Analytical Chemistry Award in recognition of her outstanding contributions to the field. Her expertise spans various aspects of analytical chemistry, including method development, validation, and application in pharmaceutical analysis. Her work is distinguished by its rigorous approach to separation science, particularly in the enantioseparation of pharmaceutical compounds using advanced HPLC techniques.

Contributions to Method Development and Validation

Dr. Saleh’s research has significantly advanced the field through the development and validation of novel analytical methods. Notably, she has pioneered stability-indicating HPLC assays for a range of pharmaceutical compounds, ensuring accurate and reliable determination of drug purity and stability. Her methods have been widely adopted and cited in the scientific community, demonstrating their robustness and applicability in pharmaceutical quality control.

Impact on Pharmaceutical Analysis

Her work on enantioseparation using chiral stationary phases has provided critical insights into the stereochemical properties of drugs, influencing pharmacokinetic studies and therapeutic efficacy assessments. These contributions have enhanced our understanding of drug interactions and metabolism, crucial for optimizing drug formulations and patient outcomes.

Innovation in Chromatographic Techniques

Dr. Saleh’s innovative approaches in chromatographic techniques have been pivotal in addressing complex analytical challenges, such as simultaneous determination of multiple enantiomers and structurally similar compounds. Her research integrates experimental design optimization with computational modeling, pushing the boundaries of analytical chemistry capabilities.

Future Directions and Research Impact

Continuing her research trajectory, Dr. Saleh aims to explore new frontiers in analytical chemistry, particularly in green analytical methods and molecular docking studies. These efforts promise to advance sustainable analytical practices and deepen our understanding of molecular interactions in drug development.